Feeley Kevin, chief financial officer of GeneSight (WGS), has filed 82 Form 4 transactions, all in a single company. The pattern is one-sided: zero open-market purchases and $5.07 million in total open-market sales. The only acquisitions on record are option exercises and grants valued at roughly $175,000, which are compensation events rather than conviction buys.
The selling has been steady and recent. Between March and September 2026, Feeley filed 16 open-market sales, with no purchases in that window. The largest single-day activity came on March 26, when five sales totaled $557,051. Another cluster on March 16 brought in $438,203 across three transactions. June 16 produced three sales worth $226,596. Smaller sales occurred on June 1 ($19,092), June 9 ($68,073), September 1 ($31,188), and September 9 ($108,220). Each sale date pairs with an option exercise at zero value, which is standard for CFOs converting vested options into shares and immediately selling them.
The dollar amounts vary widely, from $19,092 to $236,157 per transaction, but the direction is consistent. Feeley has not bought a single share on the open market across all 82 filings. The recent 16 sales, all in WGS, show a clear bias toward monetizing equity rather than accumulating it. Whether this reflects portfolio diversification, tax planning, or something else is not discernible from the filings. What the record shows is a CFO who, over eight months, sold more than $1.6 million in WGS stock while acquiring shares only through option exercises.
AI-assisted summary